Abstract
Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Current Medicinal Chemistry
Title:Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Volume: 20 Issue: 30
Author(s): Juan Carlos Palomino and Anandi Martin
Affiliation:
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Abstract: Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Export Options
About this article
Cite this article as:
Palomino Carlos Juan and Martin Anandi, Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio, Current Medicinal Chemistry 2013; 20 (30) . https://dx.doi.org/10.2174/09298673113209990166
DOI https://dx.doi.org/10.2174/09298673113209990166 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mass Spectrometry Imaging: Applications in Drug Distribution Studies
Current Drug Metabolism <i>Enoyl-Acyl Carrier Protein Reductase (INHA)</i>: A Remarkable Target to Exterminate Tuberculosis
Anti-Infective Agents Biotechnology in the Development of New Vaccines and Diagnostic Reagents Against Tuberculosis
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Searching a New Antibiotic Prototype: Snake Venoms)
Mini-Reviews in Organic Chemistry Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers
Current Medicinal Chemistry Synthesis, Screening and Docking Analysis of Novel Benzimidazolium and Benzotriazolium Compounds as Potent Anti Tubercular Agents
Anti-Infective Agents Recent Patents for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis
Current Protein & Peptide Science Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Mother-to-Child Transmission of HIV Infection and its Prevention
Current HIV Research Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Computer-aided Drug Design Investigations for Benzothiazinone Derivatives Against Tuberculosis
Combinatorial Chemistry & High Throughput Screening EDITORIAL
Current Drug Therapy L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes
Anti-Cancer Agents in Medicinal Chemistry The Role of Autophagy in Rheumatic Disease
Current Drug Targets Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development
Current Pharmaceutical Design Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Current Cancer Drug Targets Microbial Immune Evasion Employing Suppressor of Cytokine Signaling (SOCS) Proteins
Inflammation & Allergy - Drug Targets (Discontinued) Acylhydrazide Schiff Bases: DPPH Radical and Superoxide Anion Scavengers
Medicinal Chemistry